$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Octreotide LAR as Maintenance Treatment for Patients With NEC

2015-04

2018-11

2019-06

92

Study Overview

Octreotide LAR as Maintenance Treatment for Patients With NEC

This is phase II study on the efficacy of octreotide lar as maintenance treatment after first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic or esophageal neuroendocrine carcinomas.

This is a prospective, randomized, open label study on the efficacy of octreotide lar as maintenance treatment after first-line chemotherapy for patients with unresectable or metastatic gastro-entero-pancreatic or esophageal neuroendocrine carcinomas.The patients with unresectable or metastatic GEP or esophageal NEC who got CR/PR/SD after chemotherapy with IP or EP regimen qualified with the inclusion criteria are enrolled. All the patients enrolled in our study will be randomly assigned to receive octreotide LAR (group A) as maintenance treatment or follow up (group B) to disease progression. Treatment will be discontinued on withdrawal of patient consent, disease progression, unacceptable toxicity, a treatment delay of >2 weeks, or major protocol violations, after which patients were followed up every 3 months for a minimum of 12 months.

  • Gastro-entero-pancreatic Carcinoma
  • Esophageal Neuroendocrine Carcinoma
  • DRUG: Octreotide lar
  • BJT-NEC-002

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2015-04-01  

N/A  

2015-04-06  

2015-04-06  

N/A  

2015-04-07  

2015-04-07  

N/A  

2015-04  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
NO_INTERVENTION: control group

EXPERIMENTAL: Octreotide LAR treatment

The patients with unresectable or metastatic GEP or esophageal NEC who got CR/PR/SD after chemotherapy with IP or EP regimen qualified with the inclusion criteria are enrolled. All the patients enrolled in our study will be randomly assigned to receive oc

DRUG: Octreotide lar

Primary Outcome MeasuresMeasure DescriptionTime Frame
PFS3 years
Secondary Outcome MeasuresMeasure DescriptionTime Frame
OS3 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Lin Shen, Prof

Phone Number: +86 10 88196175

Email: lin100@medmail.com.cn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Histologic diagnosis of high grade (poorly differentiated) gastro-entero-pancreatic neuroendocrine carcinoma. 2. High grade neuroendocrine carcinoma of esophageal or unknown primary site (if a pulmonary primary has been excluded) 3. Metastatic or unresectable disease 4. Measurable disease 5. Accepted chemotherapy with EP or IP regimen for no less than three months 6. Effectiveness with CR/PR/SD 7. Informed consent 8. Performance status of 0 or 1 9. Adequate bone marrow function (defined as absolute neutrophil count [ANC] >= 1500, platelet count [PLT] >= 75,000 and a hemoglobin [Hgb] >= 9). 10. Adequate hepatic function with a bilirubin of <= 2.0 mg/dl, and aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) <= 2.5 times the upper limits of normal, unless caused by liver metastasis. If caused by metastasis, then should be SGPT and SGOT <= 5 times the upper limits of normal.
    Adequate renal function defined as serum creatinine <= 1.5 mg/dl.
    Exclusion Criteria:
    1. Patients who are on EP or IP chemotherapy for less than three months . 2. Effectiveness with PD. 3. Patients with brain metastases are not eligible. 4. Patients with New York Heart Association (NYHA) Class III or IV heart disease are not eligible as well as those patients with history of angina, myocardial infarction, or congestive heart failure within six months. 5. Pregnant or lactating women. All women of child bearing potential must have a negative pregnancy test prior to entry into the study. All patients of child bearing potential must be advised of the importance of avoiding pregnancy and using appropriate methods of contraception while participating in this investigational trial. 6. Patients with serious complicated infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapy. 7. Patients with psychiatric disorders rendering them incapable of complying with the requirements of the protocol. 8. Patients with serum calcium > 12 mg/dl or symptomatic hypercalcemia under treatment. 9. Patients with osseous metastasis as only site of disease. 10. Patients with any concurrent active malignancy other than non-melanoma skin cancers or carcinoma-in-situ of the cervix. Patients with previous malignancies but without evidence of disease for > 5 years will be allowed to enter the trial. 11. Patients with known Gilbert's syndrome are ineligible.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

NPCF Pop up

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate